Insight Molecular Diagnostics (IMDX) Other Accumulated Expenses (2016 - 2026)

Insight Molecular Diagnostics has disclosed Other Accumulated Expenses across 7 years of filings, most recently posting $2.7 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $2.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 million (changed N/A YoY), and the FY2025 annual result was $2.8 million, up 335.74% from the prior year.
• Other Accumulated Expenses came in at $2.7 million for Q1 2026 at Insight Molecular Diagnostics, down from $2.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.8 million in Q4 2025 to a low of $638000.0 in Q4 2024.
• The 3-year median for Other Accumulated Expenses is $2.7 million (2026), against an average of $2.1 million.
• Peak annual rise in Other Accumulated Expenses reached 335.74% in 2025, while the deepest fall reached 335.74% in 2025.
• Insight Molecular Diagnostics' Other Accumulated Expenses stood at $638000.0 in 2024, then surged by 335.74% to $2.8 million in 2025, then dropped by 1.58% to $2.7 million in 2026.
• The last three Other Accumulated Expenses figures came in at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $638000.0 (Q4 2024), per Business Quant data.